Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

• Revenue in USD (TTM)443.00k
• Net income in USD-37.03m
• Incorporated2007
• Employees23.00

• Location
  Trevena Inc955 Chesterbrook Boulevard, Suite 110CHESTERBROOK 19087United StatesUSA
• Phone+1 (610) 354-8840
• Fax+1 (302) 636-5454
• Websitehttps://www.trevena.com/